Scarica l'app Stockscreener
2.1899
4.81%
0.1099
Actuate Therapeutics Inc Borsa (ACTU) Ultime notizie
B.Riley cuts Actuate Therapeutics stock price target on revenue timing - Investing.com Canada
12 Health Care Stocks Moving In Tuesday's After-Market Session - Benzinga
Actuate Therapeutics Reports Significant Survival Improvement in Phase 2 Trial of Elraglusib for Metastatic Pancreatic Cancer - Quiver Quantitative
Pancreatic cancer trial doubled one-year survival in study - Stock Titan
ACTU Maintained by HC Wainwright & Co. -- Price Target Lowered t - GuruFocus
H.C. Wainwright Maintains Actuate Therapeutics(ACTU.US) With Buy Rating, Cuts Target Price to $15 - Moomoo
Netflix To Rally Around 15%? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
H.C. Wainwright lowers Actuate Therapeutics price target on strategy shift By Investing.com - Investing.com Canada
H.C. Wainwright lowers Actuate Therapeutics price target on strategy shift - Investing.com
Activity Recap: Can Actuate Therapeutics Inc scale operations efficiently2026 Price Action Summary & Weekly Stock Breakout Alerts - baoquankhu1.vn
Published on: 2026-04-09 23:48:44 - baoquankhu1.vn
Aug Levels: Does Actuate Therapeutics Inc have consistent dividend growth2026 Intraday Action & Community Consensus Trade Signals - baoquankhu1.vn
Profit Review: Is Actuate Therapeutics Inc benefiting from innovation trendsWeekly Trade Analysis & Consistent Return Strategy Ideas - baoquankhu1.vn
Actuate Therapeutics (NASDAQ:ACTU) Raised to Hold at Wall Street Zen - MarketBeat
ACTU Technical Analysis & Stock Price Forecast - Intellectia AI
Aug Setups: Is Actuate Therapeutics Inc stock showing strong momentum2026 Short Interest & Accurate Intraday Trading Signals - baoquankhu1.vn
Actuate Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
Actuate Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Actuate Therapeutics: Poised for Potential $200M+ Pediatric Priority Review Vouchers and Transformative Combinations in RAS-Driven Cancers - Finviz
Aug Levels: Is Actuate Therapeutics Inc benefiting from innovation trends2026 Retail & Safe Entry Point Identification - baoquankhu1.vn
Aug Outlook: Can Actuate Therapeutics Inc scale operations efficiently2026 Selloffs & Entry Point Confirmation Signals - baoquankhu1.vn
Actuate Therapeutics, Inc.: Fundamental Analysis and Financial Ratings | ACTU | US0050831009 - marketscreener.com
Aug Shorts: Can Actuate Therapeutics Inc outperform under higher oil pricesWeekly Trade Summary & Reliable Momentum Entry Alerts - baoquankhu1.vn
Voss Capital LP Boosts Stake in Actuate Therapeutics, Inc. $ACTU - MarketBeat
How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06% - MSN
Actuate Therapeutics Inc expected to post a loss of 24 cents a shareEarnings Preview - TradingView
Actuate Therapeutics Launches Strategic Research Initiative to Combine Elraglusib with RAS Inhibitors - Bitget
RSI Check: Is Actuate Therapeutics Inc stock showing strong momentumWeekly Investment Recap & Safe Capital Growth Stock Tips - baoquankhu1.vn
Actuate Therapeutics files $250M mixed securities shelf - MSN
Will Actuate Therapeutics Inc. stock gain from lower inflationPortfolio Update Summary & Reliable Price Breakout Signals - Naître et grandir
Actuate Therapeutics (NASDAQ:ACTU) Rating Lowered to Sell at Wall Street Zen - MarketBeat
Activity Recap: How buybacks impact Actuate Therapeutics Inc. stock valueMarket Weekly Review & Safe Capital Allocation Plans - Naître et grandir
Actuate Therapeutics to Present at The Citizens Life Sciences Conference - Bitget
Actuate Therapeutics, Inc. Announces Presentation at Citizens Life Sciences Conference in Miami Beach - Quiver Quantitative
Actuate Therapeutics to Present at The Citizens Life Sciences Conference - GlobeNewswire Inc.
ACTUActuate Therapeutics Inc Latest Stock News & Market Updates - Stock Titan
ACTU Technical Analysis & ETF Price Forecast - Intellectia AI
Actuate Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference - The Manila Times
Actuate Therapeutics, Inc. to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026 - Quiver Quantitative
ACTU Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Is Actuate Therapeutics Inc. stock undervalued right nowMarket Performance Report & Daily Stock Trend Watchlist - mfd.ru
Actuate Therapeutics (NASDAQ:ACTU) Rating Increased to Hold at Wall Street Zen - Defense World
ACTU PE Ratio & Valuation, Is ACTU Overvalued - Intellectia AI
Is Actuate Therapeutics Inc. stock risky to hold nowPortfolio Update Report & Technical Confirmation Trade Alerts - mfd.ru
A | Will SIMAU announce a stock splitJuly 2025 Trends & Stepwise Entry and Exit Trade Signals - mfd.ru
Actuate Therapeutics (NASDAQ:ACTU) Shares Down 3.6%Here's What Happened - MarketBeat
What is the long term forecast for GATES GROUP Inc. stockJuly 2025 Selloffs & AI Enhanced Trading Signals - baoquankhu1.vn
Published on: 2026-02-07 16:03:44 - baoquankhu1.vn
Actuate Therapeutics registers 1.33M shares for resale by investors - MSN
Patterns Watch: Is Actuate Therapeutics Inc benefiting from innovation trendsJuly 2025 Sentiment & Risk Managed Investment Entry Signals - baoquankhu1.vn
Decliners Report: Is Actuate Therapeutics Inc benefiting from innovation trendsBreakout Watch & Daily Profit Maximizing Tips - baoquankhu1.vn
Becoming A Backbone Therapy: Lessons Learned With Actuate Therapeutics - Clinical Leader
Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt - Yahoo Finance
Sectors Review: Will Actuate Therapeutics Inc stock benefit from M AJuly 2025 Trade Ideas & Capital Efficiency Focused Strategies - baoquankhu1.vn
Actuate Therapeutics plans phase 1/2 trial of oral cancer drug - Investing.com Nigeria
2.68%
0.34%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):